Transdermal estrogen therapy

References

• Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynecol Reprod Biol 1995; 59(1):57–60
   Google Scholar
• Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982–1992. Obstet Gynecol 1995; 85(1):6–10
   Google Scholar
• Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Saf 1993: 9(5):365–79
   Google Scholar
• Bagne CA, Paulissen JB, Luscombe FA. The effect of Fempatch, a 7-day matrix estradiol transdermal system, on quality of life in menopausal women. Presented before the 43d Annual ACOG Clinical Meeting. San Francisco: 1995 May
   Google Scholar
• Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168(3 Pt 1):824–30
   PubMed Web of Science ®Google Scholar
• Nilsson KE, Heimer GM. Ultra-low- dose transdermal estrogen therapy in postmenopausal urogenital estrogen deficiency—a placebo-controlled study. Menopause: J North Am Menopause Soc 1994; 1(4): 191–7
   Google Scholar
• Speroff L, Whitcomb R, Kempfert N, et al. Efficacy and tolerance of Fempatch, a low dose, 7-day matrix estradiol transdermal system for the treatment of menopausal symptoms. Presented before the 43d Annual ACOG Clinical Meeting. San Francisco: 1995 May
   Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117(12): 1016–37
   PubMed Web of Science ®Google Scholar
• Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274(7):539–44
   Google Scholar
• Cheang A, Sitruk-Ware R, Samsioe G. Transdermal oestradiol and cardiovascular risk factors. Br J Obstet Gynaecol 1994; 101(7):571–81
   Google Scholar
• Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100(2): 482–8
   Google Scholar
• Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int J Fertil 1993; 38(2):79–91
   PubMedGoogle Scholar
• Sack MN, Rader DJ, Cannon RO 3d. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343(8892):269–70
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Soldani R, Carriero PL, et al. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992; 74(6):1396–400
   PubMed Web of Science ®Google Scholar
• Prelevic GM, Beljic T. The effect of oestrogen and progestogen replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 1994; 20(1):37–44
   Google Scholar
• Melton LJ 3d. How many women have osteoporosis now? J Bone Miner Res 1995; 10(2):175–7
   Google Scholar
• NIH Consensus Development Conference Summary. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94(6):646–50
   Google Scholar
• Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122(1):9–16
   PubMed Web of Science ®Google Scholar
• Hillard TC, Whitcroft SJ, Marsh MS, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994; 4(6):341–8
   Google Scholar
• Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117(1): 1–9
   PubMed Web of Science ®Google Scholar
• Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am 1994; 21(2):219–29
   PubMed Web of Science ®Google Scholar
• Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332(24):1589–93
   PubMed Web of Science ®Google Scholar
• Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. (Editorial) Am Heart J 1995; 129(6):1237–8
   PubMed Web of Science ®Google Scholar
• Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990; 40(4):561–82
   Google Scholar
• McCarthy T, Dramusic V, Ratnam S. Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate. Am J Obstet Gynecol 1992; 166(6 Pt 2). 2005–10
   Google Scholar
• Sagraves R, O'Connell MB, Carson DS, et al. Therapeutic options for osteoporosis. APhA Special Report. Washington, DC: American Pharmaceutical Association, 1993
   Google Scholar
• Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336(8710):265–9
   PubMed Web of Science ®Google Scholar
• Boyd RA, Zegarac EA, Eldon MA, et al. Pharmacokinetic characterization of a 7-day 17b-estradiol transdermal delivery system in healthy postmenopausal women. (Abstr) Pharm Res 1993; 10:S332
   Google Scholar
• Heuman R, Larsson-Cohn U, Hammar M, et al. Effects of postmenopausal ethinylestradiol treatment on gallbladder bile. Maturitas 1980; 2(1):69–72
   Google Scholar
• Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994; 83(1):5–11
   Google Scholar
• Evans MP, Fleming KC, Evans JM. Hormone replacement therapy: management of common problems. Mayo Clin Proc 1995; 70(8):800–5
   Google Scholar
• Polvani F, Zichella L, Bocci A, et al. A randomized comparative study for the clinical evaluation of hormone replacement by transdermal and oral routes. Clin Exp Obstet Gynecol 1991; 18(4):207–13
   Google Scholar
• Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994; 20(2–3):91–9
   Google Scholar
• Balfour JA, McTavish D. Transdermal estradiol: a review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs Aging 1992; 2(6):487–507
   Google Scholar
• Davis GF, Winter L. Cumulative irritation study of placebo transdermal estrogen patches. Curr Ther Res 1987; 42(4):712–9
   Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3):199–208
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995; 85(2): 304–13
   PubMed Web of Science ®Google Scholar
• Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86(2):306–16
   Google Scholar